Pune, Nov. 18, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global Spinal Muscular Atrophy Treatment Market will clock US$ 3.41 billion by 2030. The rapidly increasing adoption of digitalization due to growing urbanization is a major driver for the Spinal Muscular Atrophy Treatment Market. This exclusive information is published by Growth Plus Reports in its report titled “Spinal Muscular Atrophy Treatment Market – Global Outlook & Forecast 2022-2030
Download Sample PDF Brochure of Spinal Muscular Atrophy Treatment Market:
https://growthplusreports.com/inquiry/request-sample/spinal-muscular-atrophy-treatment-market/7977
Market Drivers
The global spinal muscular atrophy (SMA) therapy market is anticipated to show notable expansion throughout the anticipated period. The rise in spinal muscular atrophy cases and public knowledge of this rare medical condition and its current therapies contribute to the market expansion. The market is also expected to grow due to a robust product pipeline, expanding strategic alliances and acquisitions, rising R&D expenditures, and technological innovation. The availability of reimbursement for such a rare illness therapy and the ongoing introduction of innovative treatment strategies and products with improved outcomes all contribute to the growth of the global spinal muscular atrophy treatment market.
The global spinal muscular atrophy treatment market has been analyzed from four perspectives – by type, drug type, distribution channel, and region.
Excerpts from ‘By Drug Type Segmentation’
Based on drug type in the global spinal muscular atrophy treatment market has been segmented into
- Onasemnogen Abeparvovec
- Nusinersen
Nusinersen leads the global market with the largest market share. This development can be linked to a better impact on SMA patients. This medication improves the quality of life by reducing the effects of SMA on the patient. It also aids in raising the survival motor neuron (SMN) protein, which restores normal muscle and nerve function. Furthermore, nusinersen extended the survival rate of 2-year-old children in the clinical study, demonstrating effective clinical findings. These elements are hence the motivating force behind the expansion of this market. Simultaneously, onasemnogen abeparvovec is also growing at a good pace due to the increasing adoption of treating SMA, thereby contributing to the growth of spinal muscular atrophy treatment globally.
Excerpts from ‘By Region Segmentation’
The global spinal muscular atrophy treatment market has been segmented into
- North America
- Europe
- Asia Pacific
- The Rest Of The World
North America currently holds the largest revenue share in the global spinal muscular atrophy market and is anticipated to keep this position throughout the forecast period. The quick uptake of improved technology dominates North America’s spinal muscular atrophy treatment market, sophisticated healthcare infrastructure with high healthcare expenditures, and a sizeable market player base. In addition, increased R&D investments, increased strategic partnerships and collaborations, and improved reimbursement policies for rare diseases contribute to the market expansion in this area.
Excerpts from ‘Competitive Landscape’
The prominent players operating in the global spinal muscular atrophy treatment market are
- Astellas Pharma Inc.
- Novartis Ag
- Biogen Inc.
- Genentech Inc. (F. Hoffmann-La Roche Ltd.)
- Genzyme Corporation
- Ionis Pharmaceuticals Inc.
- Astrazeneca Plc.
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited
- Chugai Pharmaceutical Co. Ltd. (F. Hoffmann-La Roche Ltd.)
- Cytokinetics Inc.
- Catalyst Pharmaceuticals Inc.
Inquire Before Buying This Research Report:
https://growthplusreports.com/inquiry/before-buying/spinal-muscular-atrophy-treatment-market/7977
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2020
- Base Year – 2021
- Forecasted Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trend (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints
- Opportunities
- GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET- ANALYSIS & FORECAST, BY TYPE
- Type I
- Type II
- Others (Type III and Type IV)
- GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET- ANALYSIS & FORECAST, BY DRUG TYPE
- Onasemnogen Abeparvovec
- Nusinersen
- GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET- ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
TOC Continue…
Scope of the Report:
| Report Attribute | Details |
| Market size value in 2021 | US$ 1.2 billion |
| Revenue forecast in 2030 | US$ 3.41 billion |
| Growth Rate | CAGR of 12.3% from 2022 to 2030 |
| Base year for estimation | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | by type, drug type, distribution, and region. |
| Regional scope | North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pipeline Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Quickly Purchase Premium Copy of Spinal Muscular Atrophy Treatment Market Report:
https://growthplusreports.com/checkout?_token=yJlb0doVVx9ZNTHLBgNorTMrStdrzr7C6hHGosHA&report_id=7977&license=Single
About Us
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
CONTACT: Manan Sethi Director, Market Insights Email: [email protected] Phone no: +91 96545 76783 Web: https://growthplusreports.com/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Mango Bunch takes no editorial responsibility for the same.